I-MAB (IMAB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
I-Mab, a global biotech firm focused on cancer immunotherapies, has appointed Sean Fu as its permanent CEO. With over 20 years in the life sciences industry, Fu aims to advance I-Mab’s clinical programs and strategy. His leadership is expected to drive the company towards significant milestones in the development of transformative therapies.
For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.
